As part of an NIAID/DAIT initiative we have been selected to participate in a multicenter project, namely Immunophenotyping assessment in a COVID-19 Cohort (IMPACC), aimed to collect and distribute patient samples and to and analyze the immune responses of 2000 COVID19 patients using specific designated cores. The main purpose of this nationwide immunophenotyping protocol in high impact COVID-19 areas is to perform detailed immunophenotyping and analysis of the host factors that may predict or predispose to resolution of infection versus disease progression and its consequences. The protocol has been designed to inform disease progression dynamics and related biomarkers; and conduct detailed, longitudinal immunophenotyping (presentation through disease progression) that includes measures of viral load to understand the interplay between viral load and immune pathology in disease progression. There is an emphasis on the clinical progression by including all aspects of clinical characterization that will be needed to match immunopathogenesis with each disease stage within each patient. IMPACC builds on the cohorts and clinical resources and technology developed by the NAIAD/DAIT funded Clinical centers for Human Immunology (CCHI) and the Human Immunology Project Consortia (HIPC). Thus, our team has been selected by DAIT to participate, since Dr. Fernandez-Sesma is currently the PI of one of the HIPC centers, named DHIPC, which studies human immune responses to dengue, chikungunya and Zika virus infection and vaccination and Dr. Adeeb Rahman is also a crucial member of the same HIPC center and will be the Immonophenotyping core leader for this application. Additionally, other members of the team have been selected to participate based on their expertise in clinical sample collection and processing in hospital settings to analyze responses to respiratory viral infections, including viral sequencing and viral load measurement. Thus, this administrative supplement to our parent HIPC grant, named Mt Sinai IMPACC is within the scope of our parent HIPC award, since it is focused on the study of human immune responses to a viral infection. The team gathered for this application includes Dr. Viviana Simon, leading the clinical/sample collection core, Dr. Adeb Rahman, that will lead the immunopheotyping core, Dr. Florian Krammer, leading the serology Core, Dr. Harm Van Bakel, leading the virus sequencing core as well as Dr. Adolfo Garcia- Sastre as a co-investigator and Dr. Jaime Hook as a pulmonologist in the clinic. With this team and the availability of clinical samples and the appropriate resources and biocontainment at our site we are poised to provide samples and to analyze the different immune and viral parameters that will help us understand disease severity and progression in during the COVID19 pandemic. Mount Sinai Hospital is located in New York City, which is at the epicenter of this pandemic in the US and is already treating hundreds of COVID pa...